Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aflibercept -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aflibercept -

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - colorectal neoplasms - antineoplastic agents - treatment of metastatic colorectal cancer (mcrc).

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - cetuximab, chimeric antibody - infusion, solution - 5mg/ml - cetuximab, chimeric antibody 5mg/ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - ramucirumab - solution for infusion - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - ramucirumab - solution for infusion - 10mg/1ml

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - lapatinib ditosylate 405.0mg eqv lapatinib - tablet, film coated - 250.00mg - lapatinib ditosylate 405.0mg eqv lapatinib 250.00mg

Singapore - English - HSA (Health Sciences Authority)

amgen biotechnology singapore pte ltd - panitumumab - infusion, solution concentrate - 100 mg/vial - panitumumab 100 mg/vial

United States - English - NLM (National Library of Medicine)

imclone llc - cetuximab (unii: pqx0d8j21j) (cetuximab - unii:pqx0d8j21j) - cetuximab 2 mg in 1 ml - erbitux® is indicated: - in combination with radiation therapy for the initial treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (scchn). - in combination with platinum-based therapy with fluorouracil for the first-line treatment of patients with recurrent locoregional disease or metastatic scchn. - as a single-agent for the treatment of patients with recurrent or metastatic scchn for whom prior platinum-based therapy has failed. erbitux is indicated for the treatment of k-ras wild-type, epidermal growth factor receptor (egfr)-expressing, metastatic colorectal cancer (mcrc) as determined by an fda-approved test [see dosage and administration (2.2)] : - in combination with folfiri (irinotecan, fluorouracil, leucovorin) for first-line treatment, - in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, - as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.

United States - English - NLM (National Library of Medicine)

eli lilly and company - ramucirumab (unii: d99yvk4l0x) (ramucirumab - unii:d99yvk4l0x) - ramucirumab 10 mg in 1 ml - cyramza® , as a single agent or in combination with paclitaxel, is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction (gej) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. cyramza, in combination with erlotinib, is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. cyramza, in combination with docetaxel, is indicated for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with disease progression on or after platinum-based chemotherapy. patients with epidermal growth factor receptor (egfr) or anaplastic lymphoma kinase (alk) genomic tumor aberrations should have disease progression on fda-approved therapy for these aberrations prior to receiving cyramza. cyramza, in combination with folfiri (irinote